Gates Package — page 42
of 1375 pages
← p.41 p.43 → · this page in the original PDF · package
www.cbrintl.com<http://www.cbrintl.com><https://email.healthsystem.virginia.edu/owa/UriBlockedError.aspx><http:/
/www.cbrintl.com/>
This electronic transmission (including any and all attachments) is intended solely for the use of the individual or entity
to whom it is addressed and may contain information that is privileged and/or confidential. If you are not the intended
recipient of this electronic transmission, you are hereby notified that any disclosure, copying or distribution, or the
taking of any action in reliance upon the contents of this electronic transmission, is strictly prohibited, and you are
further requested to purge this electronic transmission and all copies thereof from your computer system.
From: Marshall Hoke
Sent: Wednesday, July 30, 2014 11:25 AM
To: 'Larry Zeitlin'; Trina Racine; deborah scott
Cc: Frederick G *HS Hayden; Gary (Public Health Agency of Canada) Kobinger;
HR
© 1 ih. gov< mailto IO
nih. gov><mailto {MH nih.gov> [C] Olinger; Peter (NIH/NIAID) [E]
Jahrlin,
ike Hensley; Lisa (NIH/NIAID) [E] Hensley; Miles Brennan; Tara Nyhuis
Subject: RE: Combining the existing Phase 1 with a Therapeutic Portion
Dear All,
At the request of Dr. Zeitlin in the email below, we would like to propose a teleconference this Friday (8/1/2014) at 7
AM PDT/ 8 AM MDT/ 9 AM CDT/ 4 PM CEST. Alternatively, we would propose a teleconference next Tuesday (8/5/2014)
at 7 AM PDT/ 8 AM MDT/ 9 AM CDT/ 4 PM CEST if Friday is not an option for the group. Please let us know your
availability and we will draft a preliminary agenda and distribute it to everyone along with dial-in information.
Thank you,
Marshall
Marshall Hoke, B.A.
Technical Associate
CBR International Corp. (r)
www.cbrintl.com<http://www.cbrintl.com><https://email.healthsystem.virginia.edu/owa/UrlBlockedError.aspx><http:/
/www.cbrintl.com/>
This electronic transmission (including any and all attachments) is intended solely for the use of the individual or entity
to whom it is addressed and may contain information that is privileged and/or confidential. If you are not the intended
recipient of this electronic transmission, you are hereby notified that any disclosure, copying or distribution, or the
taking of any action in reliance upon the contents of this electronic transmission, is strictly prohibited, and you are
further requested to purge this electronic transmission and all copies thereof from your computer system.
From: Larry Zeitlin [mailto {©
mappbio.com]
Sent: Wednesday, July 30, 2014 10:55 AM
To: Trina Racine; deborah scott
Cc: Frederick G *HS Hayden; Gary (Public Health Agency of Canada) Kobinger;
HR
© 1b. cov< mailto
FO nin.gov><mailto
FO nih.gov> [C] Olinger; Peter (NIH/NIAID) [E]
Jahrling;
Mike Hensley; Lisa (NIH/NIAID) [E] Hensley; Miles Brennan; Tara Nyhuis; Marshall Hoke
Subject: Re: Combining the existing Phase 1 with a Therapeutic Portion
Hi all,
This is our OCR of the page, with running headers and footers removed. The
Committee's PDF
is authoritative; quote from it. Machine-readable, including the uncleaned
text: /api/page/gates/42
Records on this page
| Record | Date | Type | Pages |
|---|---|---|---|
| gates:email:00012 | 2014-07-30 | 42–43 | |
| RE: Combining the existing Phase 1 with a Therapeutic Portion | 2014-08-03 | 40–42 |